Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil adjunctive therapy in drug-resistant focal epilepsy
NCT03739840Phase 3Terminated
- Sponsor
- UCB
- Start
- Mar 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of padsevonil in epilepsy, focal epilepsy, sponsored by UCB. Started Mar 2019; status: terminated.
02
Drugs
padsevonil
03
Conditions
epilepsyfocal epilepsy
Beyond the preview
Go deeper on NCT03739840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739840.